These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7172676)

  • 41. Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
    Raymond EG; Singh M; Archer DF; Saxena BB; Baker J; Cole D
    Fertil Steril; 1996 Dec; 66(6):954-61. PubMed ID: 8941061
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adrenocortical function of patients using oral contraceptives.
    Kauppila A; Järvinen PA; Ylöstalo P; Reinilä M
    Acta Obstet Gynecol Scand; 1974; 53(2):155-9. PubMed ID: 4362662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation between the serum norethindrone (NET) levels attained after insertion of a silastic implant releasing norethindrone acetate and the endogenous hormones particularly progesterone.
    Laumas V; Jain AK; Jha P; Rahman SA; Kumar D; Malik BK; Sarkar NN; Takkar D; Hingorani V; Laumas KR
    Contraception; 1981 Feb; 23(2):211-25. PubMed ID: 6786828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The contraceptive efficacy of 10mg or 25mg of norethindrone given orally on day 15-22 of the human menstrual cycle.
    Nygren KG; Johansson ED; Wide L
    Contraception; 1974 Mar; 9(3):249-56. PubMed ID: 4442274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radioimmunoassay of plasma ethinylestradiol in the presence of circulating norethindrone.
    Stanczyk FZ; Gale JA; Goebelsmann U; Nerenberg C; Matin S
    Contraception; 1980 Nov; 22(5):457-70. PubMed ID: 7471737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radioimmunoassay of norethindrone: peripheral plasma levels after oral administration to humans and rhesus monkeys.
    Nygren KG; Lindberg P; Martinsson K; Bosu WT; Johansson ED
    Contraception; 1974 Mar; 9(3):265-78. PubMed ID: 4442276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New long-acting injectable microcapsule contraceptive system.
    Beck LR; Cowsar DR; Lewis DH; Gibson JW; Flowers CE
    Am J Obstet Gynecol; 1979 Oct; 135(3):419-26. PubMed ID: 114054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles.
    Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC
    Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term use of depot-norethisterone enanthate: effect on blood coagulation factors and menstrual bleeding patterns.
    McEwan JA; Griffin M
    Contraception; 1991 Dec; 44(6):639-48. PubMed ID: 1773620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Single- and multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis.
    Price TM; Dupuis RE; Carr BR; Stanczyk FZ; Lobo RA; Droegemueller W
    Am J Obstet Gynecol; 1993 May; 168(5):1400-6. PubMed ID: 8498419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma protein binding of norethisterone.
    Odlind V; Victor A; Johansson ED
    Contraception; 1982 May; 25(5):457-62. PubMed ID: 7201915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest.
    el-Raghy I; Back DJ; Makeram M; Salem H; Osman F; Fathalla M; Orme ML
    Contraception; 1986 Apr; 33(4):379-84. PubMed ID: 3089683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate.
    Vose CW; Butler JK; Williams BM; Stafford JE; Shelton JR; Rose DA; Palmer RF; Breckenridge AM; Orme ML; Serlin MJ
    Contraception; 1979 Feb; 19(2):119-27. PubMed ID: 428229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intra- and interindividual variations in contraceptive steroid levels during 12 treatment cycles: no relation to irregular bleedings.
    Jung-Hoffmann C; Kuhl H
    Contraception; 1990 Oct; 42(4):423-38. PubMed ID: 2147887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of oral contraceptive steroids after morning or evening administration.
    Kiriwat O; Fotherby K
    Contraception; 1983 Feb; 27(2):153-60. PubMed ID: 6851554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.
    Furuhjelm M; Carlström K
    Acta Obstet Gynecol Scand; 1977; 56(4):351-61. PubMed ID: 602703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioequivalence of norethindrone and ethinyl estradiol for two different weight tablets with the same hormonal content.
    Saperstein S; Edgren RA; Ellis DJ; Lee GJ; Kushinsky S; Olmsted A; Mroszczak E
    Contraception; 1986 Jun; 33(6):547-57. PubMed ID: 3769481
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Androgenic, anabolic, estrogenic and antiestrogenic effects of desogestrel and lynestrenol: effects on serum proteins and vaginal cytology.
    Cullberg G
    Contraception; 1984 Jul; 30(1):73-9. PubMed ID: 6236952
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of biodegradable norethisterone implants as a 6-month contraceptive system.
    Rivera R; Gaitan JR; Ortega M; Flores C; Hernandez A
    Fertil Steril; 1984 Aug; 42(2):228-32. PubMed ID: 6745456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.